National Bankshares set a C$14.00 target price on Vitalhub (TSE:VHI - Free Report) in a research note issued to investors on Tuesday morning,BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.
VHI has been the subject of a number of other research reports. Raymond James set a C$13.50 target price on shares of Vitalhub and gave the stock an "outperform" rating in a research report on Thursday, March 27th. TD Securities increased their target price on Vitalhub from C$13.00 to C$14.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of C$13.08.
View Our Latest Stock Report on Vitalhub
Vitalhub Stock Down 2.0%
Shares of TSE:VHI traded down C$0.22 during trading on Tuesday, reaching C$11.00. The stock had a trading volume of 67,962 shares, compared to its average volume of 131,183. The stock has a fifty day simple moving average of C$10.41 and a two-hundred day simple moving average of C$10.63. The firm has a market capitalization of C$595.02 million, a price-to-earnings ratio of 178.91, a P/E/G ratio of 1.18 and a beta of 1.26. Vitalhub has a 52 week low of C$6.74 and a 52 week high of C$12.34.
Insider Buying and Selling at Vitalhub
In other Vitalhub news, Director Francis Nelson Shen bought 25,000 shares of the firm's stock in a transaction dated Friday, May 16th. The shares were acquired at an average cost of C$10.23 per share, for a total transaction of C$255,750.00. Insiders own 18.57% of the company's stock.
Vitalhub Company Profile
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Read More

Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.